Systematic analyses of glutamine and glutamate metabolisms across different cancer types

Yuan Tian, Wei Du, Sha Cao, Yue Wu, Ning Dong, Yan Wang, Ying XuChinese 2017 · DOI

TL;DR

This study computationally analyzes gene expression data from 11 cancer types to map the roles of glutamine and glutamate metabolism. It reveals that while these pathways are generally upregulated in cancer, their specific contributions to key metabolic processes like nucleotide and energy synthesis vary significantly across cancer types, offering potential for targeted therapeutic strategies.

What Problem Does This Paper Address?

Cancer cells exhibit a voracious appetite for nutrients, with glutamine being a particularly favored fuel source alongside glucose. While the importance of glutamine and glutamate metabolism in cancer is recognized, a comprehensive, comparative understanding of their specific roles across diverse cancer types has been lacking. This knowledge gap hinders the development of targeted therapies that exploit these metabolic vulnerabilities. This paper aims to fill this gap by systematically analyzing how glutamine and glutamate metabolism contribute to various biological processes in 11 different human cancers.

Methods

The researchers employed a computational approach using gene expression data (RNA-seq) from The Cancer Genome Atlas (TCGA). They developed a linear regression model to assess the differential contributions of glutamine and/or glutamate to seven key biological processes in cancer versus normal tissues. This model allowed them to quantify how the expression levels of specific genes involved in metabolic pathways change between cancer and control samples and to infer the functional impact of these changes. They also used principal component analysis to estimate the expression levels of entire metabolic processes based on their rate-limiting enzymes or transporters.

Datasets

The study utilized RNA-seq gene expression data from the TCGA database for 11 human cancer types: bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD), and thyroid carcinoma (THCA). Only cancer types with at least 10 cancerous and 10 control samples were included.

Key Insights and Ideas

  • Cancer's Thirst for Glutamine: The study confirms that glutamine and glutamate influx is generally increased in most of the analyzed cancer types, highlighting their critical role in fueling cancer cell growth and survival.
  • Metabolic Heterogeneity: Despite the general upregulation, the specific contributions of glutamine and glutamate to fundamental processes like nucleotide synthesis, ATP production, and lipid synthesis are surprisingly diverse across different cancer types. This suggests that a one-size-fits-all therapeutic approach targeting these pathways might not be effective.
  • Glutamine's Limited Role in Core Synthesis: Intriguingly, glutamine appears to play a minimal or no role in purine and pyrimidine synthesis in many cancer types, except for specific instances (e.g., BRCA for purines, KIRC for pyrimidines). This challenges some existing assumptions and points to alternative metabolic routes in these cancers.
  • ROS and Antioxidant Defense: A strong positive correlation was observed between increased glutamine/glutamate metabolism and reactive oxygen species (ROS) levels. This suggests a potential role for these amino acids in cancer's antioxidant defense mechanisms, possibly through glutathione synthesis.
  • Survival Rate Link: A significant negative correlation was found between the level of change in glutamine metabolism and the 5-year survival rate across the studied cancers, implying that glutamine metabolic gene expression could serve as a prognostic indicator.

Key Results

  • 10 out of 11 cancer types showed increased influx of both glutamine and glutamate. PRAD was an exception.
  • Glutamine metabolism was significantly upregulated in LUAD, followed by COAD, KICH, HNSC, and BRCA.
  • Glutamine generally does not contribute to purine synthesis (except BRCA) or pyrimidine synthesis (except KIRC).
  • Glutamine's contribution to ATP production and nucleotide synthesis was found to be minimal or absent in most cancer types.
  • Glutamine's role in asparagine synthesis was limited to BLCA and LUAD, and in serine synthesis, it was primarily glutamate that contributed (except in HNSC).
  • A strong positive correlation (r=0.686, P=0.020) was found between increased ROS levels and glutamine metabolism.

Limitations and Future Work

The authors acknowledge a significant limitation: the use of tissue-based gene expression data, which includes contributions from non-cancerous cells (immune, stromal, fat cells). This can obscure subtle changes within cancer cells themselves. They emphasize that the observed gene expression changes should be considered substantially up- or down-regulated. Future work should focus on functional validation of these computational predictions to confirm their therapeutic potential. Further studies are needed to disentangle the precise roles of glutamine and glutamate in specific cancer types and to develop targeted therapeutic strategies based on these findings.

Summary updated

Abstract

We comprehensively predicted the roles of glutamine and glutamate metabolisms in selected metabolic pathways in cancer tissues versus control tissues, which may lead to novel approaches to therapeutic development targeted at glutamine and/or glutamate metabolism. However, our predictions need further functional validation.
BibTeX
@inproceedings{tian2017systematic,
  author = {Yuan Tian and Wei Du and Sha Cao and Yue Wu and Ning Dong and Yan Wang and Ying Xu},
  title = {{Systematic analyses of glutamine and glutamate metabolisms across different cancer types}},
  booktitle = {Chinese},
  year = {2017},
  doi = {10.1186/s40880-017-0255-y},
}
Figure